You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.


Back to the Future: Revitalizing the Role of Cholesteryl Ester Transfer Protein (CETP) Inhibition for CV Risk Reduction

  • Authors: Roxana Mehran, MD; Christie M. Ballantyne, MD
  • CME / ABIM MOC Released: 8/11/2023
  • Valid for credit through: 9/28/2023, 11:59 PM EST
Start Activity

Target Audience and Goal Statement

This activity is intended for cardiologists, primary care physicians, diabetologists/endocrinologists, neurologists, emergency medicine physicians, nurse practitioners (NPs), physician assistants (PAs), and other clinicians who treat patients with dyslipidemia.

The goal of this activity is for learners to be better able to evaluate the burden of ASCVD, the rationale for the use of additional nonstatin low-density lipoprotein cholesterol (LDL-C)-lowering therapies, as well as emerging therapies, including CETP inhibitors, with a review of mechanism, past failures, clinical safety/efficacy, and potential impact on patient outcomes.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • CETP inhibition for cardiovascular (CV) risk reduction
    • Characteristics and mechanism of action of CETP inhibitors (CETPis)
    • Clinical evidence on the use of CETPis in the setting of CV risk reduction
  • Demonstrate greater confidence in their ability to
    • Evaluate the emerging role of CETPi use as a nonstatin lipid-lowering strategy for CV risk reduction


Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to Medscape policies. Others involved in the planning of this activity have no relevant financial relationships.


  • Roxana Mehran, MD

    Professor of Medicine
    Director of Interventional Cardiovascular Research and Clinical Trials
    Icahn School of Medicine at Mount Sinai
    New York, New York


    Roxana Mehran, MD, has the following relevant financial relationships:
    Consultant or advisor for: AstraZeneca Pharmaceuticals LP; Ionis Pharmaceuticals; J-CalC; Novartis Pharmaceuticals; Novo Nordisk; Vectura
    Speaker or member of speakers bureau for: Daiichi Sankyo, Inc.; Medtronic, Inc.
    Research funding from: Abbott Laboratories; ABIOMED; Alleviant Medical; Amgen, Inc.; AM-Pharma; Arena Pharmaceuticals, Inc.; AstraZeneca Pharmaceuticals LP; Biosensors International Group, Ltd.; BIOTRONIK; Bristol Myers Squibb Company; CardiaWave; CeloNova BioSciences, Inc.; Chiesi Pharmaceuticals, Inc.; Concept Medical; Cytosorbents; Daiichi Sankyo, Inc.; Element Science; Faraday; Idorsia Pharmaceuticals, Ltd.; Janssen Pharmaceuticals; Mediasphere; Medtelligence, LLC; Medtronic, Inc.; Novartis Pharmaceuticals Corporation; OrbusNeich; Penumbra; PhaseBio Pharmaceuticals, Inc.; Philips Healthcare; Pi-Cardia; PLx Pharma Inc.; Protembis; RenalPro; RM Global; Shockwave; Vivasure
    Owns stock (privately owned) in: Elixir Medical
    Owns stock (publicly traded) in: Applied Therapeutics, Stellar Bancorp Inc.

  • Christie M. Ballantyne, MD

    Professor of Medicine
    Section of Cardiovascular Research
    Center for Cardiovascular Disease Prevention
    Baylor College of Medicine
    Houston, Texas


    Christie M. Ballantyne, MD, has the following relevant financial relationships:
    Consultant or advisor for: 89 bio; Abbott Diagnostics; Alnylam Pharmaceuticals, Inc.; Althera; Amarin Corporation plc; Amgen, Inc.; Arrowhead Pharmaceuticals, Inc.; AstraZeneca Pharmaceuticals LP; Denka Seiken; Esperion Therapeutics, Inc.; Genentech, Inc.; Gilead Sciences, Inc.; Illumina; Matinas BioPharma Inc; Merck & Co., Inc.; New Amsterdam; Novartis Pharmaceuticals; Novo Nordisk; Pfizer, Inc.; Regeneron Pharmaceuticals, Inc.; Roche Diagnostics
    Research funding from: Abbott Diagnostic; Akcea Therapeutics; Amgen, Inc.; Arrrowhead Pharmaceuticals, Inc.; Esperion Therapeutics, Inc.; Ionis Pharmaceuticals; Merck & Co., Inc.; Novartis Pharmaceuticals; Novo Nordisk; Regeneron Pharmaceuticals, Inc.; Roche Diagnostics


  • Asha P. Gupta, PharmD, RPh

    Medical Education Director, Medscape, LLC


    Asha P. Gupta, PharmD, RPh, has no relevant financial relationships.

  • Frederick Stange, DO

    Scientific Content Manager, Medscape, LLC


    Frederick Stange, DO, has no relevant financial relationships.

Compliance Reviewer

  • Amanda Jett, PharmD, BCACP

    Associate Director, Accreditation and Compliance, Medscape, LLC


    Amanda Jett, PharmD, BCACP, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.

Accreditation Statements


Interprofessional Continuing Education

In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.50 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

    College of Family Physicians of Canada Mainpro+® participants may claim certified credits for any AMA PRA Category 1 credit(s)™, up to a maximum of 50 credits per five-year cycle. Any additional credits are eligible as non-certified credits. College of Family Physicians of Canada (CFPC) members must log into Mainpro+® to claim this activity.

    Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read about the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or print it out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate, but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period, you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.


Back to the Future: Revitalizing the Role of Cholesteryl Ester Transfer Protein (CETP) Inhibition for CV Risk Reduction

Authors: Roxana Mehran, MD; Christie M. Ballantyne, MDFaculty and Disclosures

CME / ABIM MOC Released: 8/11/2023

Valid for credit through: 9/28/2023, 11:59 PM EST


A Powerpoint version of the slides from this presentation
is available for use as a professional resource from Medscape Education.

  • Print